Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $107.78 USD
Change Today -0.21 / -0.19%
Volume 10.8M
GILD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Xetra
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

John C. Martin Ph.D.

Chairman and Chief Executive Officer,Gilead Sciences Inc.
AgeTotal Calculated CompensationThis person is connected to 164 board members in 4 different organizations across 4 different industries.

See Board Relationships
63$18,957,994
As of Fiscal Year 2014

Background*

Dr. John C. Martin, Ph.D. has been the Chief Executive Officer of Gilead Sciences Inc. since April 1996 and served as its President from April 1996 to May 2008. Dr. Martin joined Gilead Sciences Inc. in October 1990 as Vice President for Research and Development. He had been with Syntex Corporation from 1978 to 1984. He served as the President of the International Society for Antiviral Research. He has been Chairman of the Board of Gilead Sciences Inc., since May 2008. ...

Read Full Background

Corporate Headquarters*

333 Lakeside Drive
Foster City, California 94404

United States

Phone: 650-574-3000
Fax: 650-578-9264

Board Members Memberships*

Director
1996-Present
Chairman and Chief Executive Officer
2009-Present
Director

Education*

PhD
The University of Chicago
MBA
Golden Gate University

Other Affiliations*

Annual Compensation*

Salary$1,605,017
Total Annual Compensation$1,605,017

Stock Options*

Restricted Stock Awards$8,386,205
All Other Compensation$7,500
Exercised Options1,687,508
Exercised Options Value$137,294,462
Exercisable Options6,517,403
Exercisable Options Value$487,624,021
Unexercisable Options675,607
Unexercisable Options Value$34,827,133
Total Value of Options$659,745,615
Total Number of Options8,880,518

Total Compensation*

Total Annual Cash Compensation$5,329,882
Total Short Term Compensation$1,605,017
Other Long Term Compensation$8,393,705
Total Calculated Compensation$18,957,994
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $107.78 USD -0.21

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Robert A. Bradway Chairman, Chief Executive Officer, President, Chairman of Executive Committee and Member of Equity Award Committee
Amgen Inc.
$1.5M
Brenton L. Saunders J.D.Chief Executive Officer, President and Director
Allergan plc
$500.0K
Kenneth C. Frazier Chairman, Chief Executive Officer and President
Merck & Co. Inc.
$1.5M
Olivier Brandicourt Chief Executive Officer and Director
Sanofi
--
Richard A. Gonzalez Chairman, Chief Executive Officer and Chairman of Executive Committee
AbbVie Inc.
$1.6M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.